Nadel Arnold, Drakopoulos Michael, Bains Harnaina K, Bar-Meir Avram, Marchese Alessandro, Lyon Alice T, Mirza Rukhsana G
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Eye (Lond). 2025 May;39(7):1337-1343. doi: 10.1038/s41433-024-03583-3. Epub 2025 Jan 25.
To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer's recommended induction phase of treatment.
Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months. Best-corrected visual acuity (BCVA), OCT, pigment epithelial detachment (PED), and macular neovascularization (MNV) parameters were analyzed at baseline and 3 months.
Thirty-two patients (38 eyes) were included in the baseline OCT characteristic analysis, 29 patients (35 eyes) in the MNV analysis, and 18 patients (21 eyes) in the PED analysis. Significant decreases in PED parameters were observed, including PED volume (mean decrease of 0.0592 mm (-19.66%; p = 0.0164), sample standard deviation (ssd) = 0.114 mm), mean height (mean decrease of 0.00871 mm (-19.16%; p = 0.0003), ssd = 0.0143 mm), and maximum height (mean decrease of 0.0242 mm (-15.28%; p = 0.002), ssd = 0.0359). Significant decreases in MNV metrics were also observed, including area (mean decrease of 0.252 mm (-9.06%; p = 0.0054), ssd = 0.519 mm), and vessel area density (mean decrease of 6.51% absolute (-8.23%; p = 0.0004), ssd = 0.0943% absolute). BCVA (logMAR) remained stable between baseline and 3 months (0.25-0.23; p = 0.34). Notably, there were no statistically significant changes in the percentage of eyes with intraretinal fluid (IRF) or subretinal fluid (SRF) between baseline and 3 months (all p > 0.05).
In recalcitrant nAMD patients who were transitioned to faricimab, patients maintained their vision while significant improvements in OCT PED and SS-OCTA MNV parameters were seen during the induction phase.
利用光学相干断层扫描（OCT）和扫频光学相干断层血管造影（SS-OCTA），对在制造商推荐的治疗诱导期转为玻璃体内注射法西单抗治疗的顽固性新生血管性年龄相关性黄斑变性（nAMD）患者眼部出现的形态学变化进行量化。
招募了54例治疗抵抗性患者（60只眼）。在0个月和3个月时获取OCT和SS-OCTA图像。分析基线和3个月时的最佳矫正视力（BCVA）、OCT、色素上皮脱离（PED）和黄斑新生血管（MNV）参数。
32例患者（38只眼）纳入基线OCT特征分析，29例患者（35只眼）纳入MNV分析，18例患者（21只眼）纳入PED分析。观察到PED参数显著降低，包括PED体积（平均降低0.0592 mm（-19.66%；p = 0.0164），样本标准差（ssd）= 0.114 mm）、平均高度（平均降低0.00871 mm（-19.16%；p = 0.0003），ssd = 0.0143 mm）和最大高度（平均降低0.0242 mm（-15.28%；p = 0.002），ssd = 0.0359）。还观察到MNV指标显著降低，包括面积（平均降低0.252 mm（-9.06%；p = 0.0054），ssd = 0.519 mm）和血管面积密度（绝对平均降低6.51%（-8.23%；p = 0.0004），ssd = 0.0943%绝对）。BCVA（logMAR）在基线和3个月之间保持稳定（0.25 - 0.23；p = 0.34）。值得注意的是，基线和3个月之间视网膜内液（IRF）或视网膜下液（SRF）眼的百分比没有统计学上的显著变化（所有p > 0.05）。
在转为法西单抗治疗的顽固性nAMD患者中，患者视力保持稳定，同时在诱导期OCT的PED和SS-OCTA的MNV参数有显著改善。
